Mobile

A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003286-17

A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour blood pressure profile superior to ibuprofen 600 mg t.i.d. in OA patients with controlled hypertension

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this trial is to demonstrate that lumiracoxib 100 mg o.d. has an improved 24-hour BP profile compared to ibuprofen 600 mg t.i.d. with respect to the effect on Ambulatory Blood Pressure Monitoring (ABPM) after 4 weeks of treatment (defined as change from baseline in average 24-hour systolic BP) in OA patients with controlled hypertension.

Critère d'inclusion

  • Osteoarthritis

Liens